{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:24:11Z","timestamp":1790245451081,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recurrent gain-of-function JAK2<jats:sup>V617F<\/jats:sup> mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1\/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2<jats:sup>V617F<\/jats:sup>-positive cells. In JAK2<jats:sup>V617F<\/jats:sup>-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1\/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba\/F3 JAK2<jats:sup>V617F<\/jats:sup> tumor burden and splenomegaly in Jak2<jats:sup>V617F<\/jats:sup> knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: downregulation of JAK2\/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative\/complementary therapeutic strategies for MPN.<\/jats:p>","DOI":"10.1038\/s41419-017-0256-4","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T12:07:20Z","timestamp":1519301240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms"],"prefix":"10.1038","volume":"9","author":[{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Alves","family":"Fenerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Scopim-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luiz","family":"Coelho-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Roberto Porto","family":"Dechandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Cristina","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Nunes","family":"Rodrigues Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Santos","family":"Scheucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda Pinto","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane Carla","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena L\u00f4bo","family":"de Figueiredo Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina E.","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","volume":"115","author":"NH Thoennissen","year":"2010","unstructured":"Thoennissen, N. H. et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115, 2882\u20132890 (2010).","journal-title":"Blood"},{"key":"256_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/leu.2010.269","volume":"25","author":"A Pardanani","year":"2011","unstructured":"Pardanani, A. et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25, 218\u2013225 (2011).","journal-title":"Leukemia"},{"key":"256_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426\u2013435 (2015).","journal-title":"N. Engl. J. Med."},{"key":"256_CR6","doi-asserted-by":"crossref","first-page":"40767","DOI":"10.18632\/oncotarget.8194","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae, Y. K. et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 7, 40767\u201340780 (2016).","journal-title":"Oncotarget"},{"key":"256_CR7","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1172\/JCI67232","volume":"123","author":"M Pollak","year":"2013","unstructured":"Pollak, M. Potential applications for biguanides in oncology. J. Clin. Invest. 123, 3693\u20133700 (2013).","journal-title":"J. Clin. Invest."},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"e74420","DOI":"10.1371\/journal.pone.0074420","volume":"8","author":"GM Leclerc","year":"2013","unstructured":"Leclerc, G. M., Leclerc, G. J., Kuznetsov, J. N., DeSalvo, J. & Barredo, J. C. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS. One. 8, e74420 (2013).","journal-title":"PLoS. One."},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/leu.2013.107","volume":"27","author":"S Scotland","year":"2013","unstructured":"Scotland, S. et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 27, 2129\u20132138 (2013).","journal-title":"Leukemia"},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2014.01.006","volume":"346","author":"C Rosilio","year":"2014","unstructured":"Rosilio, C., Ben-Sahra, I., Bost, F. & Peyron, J. F. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer Lett. 346, 188\u2013196 (2014).","journal-title":"Cancer Lett."},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-016-3037-3","volume":"78","author":"HH Zhang","year":"2016","unstructured":"Zhang, H. H. & Guo, X. L. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother. Pharmacol. 78, 13\u201326 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","volume":"116","author":"AS Green","year":"2010","unstructured":"Green, A. S. et al. The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116, 4262\u20134273 (2010).","journal-title":"Blood"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","volume":"21","author":"S Dalva-Aydemir","year":"2015","unstructured":"Dalva-Aydemir, S. et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin. Cancer Res. 21, 1161\u20131171 (2015).","journal-title":"Clin. Cancer Res."},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mc.22498","volume":"56","author":"H Gwak","year":"2017","unstructured":"Gwak, H., Kim, Y., An, H., Dhanasekaran, D. N. & Song, Y. S. Metformin induces degradation of cyclin D1 via AMPK\/GSK3beta axis in ovarian cancer. Mol. Carcinog. 56, 349\u2013358 (2017).","journal-title":"Mol. Carcinog."},{"key":"256_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.13","volume":"3","author":"WY Shi","year":"2012","unstructured":"Shi, W. Y. et al. Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 3, e275 (2012).","journal-title":"Cell Death Dis."},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/leu.2011.269","volume":"26","author":"C Grimaldi","year":"2012","unstructured":"Grimaldi, C. et al. AMP-dependent kinase\/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 26, 91\u2013100 (2012).","journal-title":"Leukemia"},{"key":"256_CR17","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1182\/blood-2011-01-332783","volume":"118","author":"E Vakana","year":"2011","unstructured":"Vakana, E., Altman, J. K., Glaser, H., Donato, N. J. & Platanias, L. C. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 118, 6399\u20136402 (2011).","journal-title":"Blood"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1038\/sj.onc.1209615","volume":"25","author":"C Giacinti","year":"2006","unstructured":"Giacinti, C. & Giordano, A. RB and cell cycle progression. Oncogene 25, 5220\u20135227 (2006).","journal-title":"Oncogene"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","volume":"19","author":"M Warmuth","year":"2007","unstructured":"Warmuth, M., Kim, S., Gu, X. J., Xia, G. & Adrian, F. Ba\/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19, 55\u201360 (2007).","journal-title":"Curr. Opin. Oncol."},{"key":"256_CR20","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e02242 (2014).","journal-title":"Elife"},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"40141","DOI":"10.18632\/oncotarget.5653","volume":"6","author":"L Mazzacurati","year":"2015","unstructured":"Mazzacurati, L. et al. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget 6, 40141\u201340157 (2015).","journal-title":"Oncotarget"},{"key":"256_CR22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109\u20133117 (2010).","journal-title":"Blood"},{"key":"256_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1126\/science.335.6064.29","volume":"335","author":"G Taubes","year":"2012","unstructured":"Taubes, G. Cancer research. Cancer prevention with a diabetes pill? Science 335, 29 (2012).","journal-title":"Science"},{"key":"256_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/CAD.0000000000000266","volume":"26","author":"R Shi","year":"2015","unstructured":"Shi, R. et al. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anticancer Drugs 26, 913\u2013922 (2015).","journal-title":"Anticancer Drugs"},{"key":"256_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","volume":"39","author":"F Wang","year":"2015","unstructured":"Wang, F. et al. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leuk. Res. 39, 1421\u20131427 (2015).","journal-title":"Leuk. Res."},{"key":"256_CR26","doi-asserted-by":"publisher","first-page":"51435","DOI":"10.18632\/oncotarget.9843","volume":"7","author":"J Velez","year":"2016","unstructured":"Velez, J. et al. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget 7, 51435\u201351449 (2016).","journal-title":"Oncotarget"},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2013.04.015","volume":"336","author":"C Rosilio","year":"2013","unstructured":"Rosilio, C. et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL\/T-LL cancer cells. Cancer Lett. 336, 114\u2013126 (2013).","journal-title":"Cancer Lett."},{"key":"256_CR28","first-page":"516460","volume":"2015","author":"A Rodriguez-Lirio","year":"2015","unstructured":"Rodriguez-Lirio, A. et al. Metformin induces cell cycle arrest and apoptosis in drug-resistant leukemia cells. Leuk. Res. Treat. 2015, 516460 (2015).","journal-title":"Leuk. Res. Treat."},{"key":"256_CR29","doi-asserted-by":"publisher","first-page":"22624","DOI":"10.18632\/oncotarget.4168","volume":"6","author":"S Bruno","year":"2015","unstructured":"Bruno, S. et al. Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. Oncotarget 6, 22624\u201322640 (2015).","journal-title":"Oncotarget"},{"key":"256_CR30","doi-asserted-by":"crossref","first-page":"18965","DOI":"10.18632\/oncotarget.7879","volume":"7","author":"R Voltan","year":"2016","unstructured":"Voltan, R. et al. Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. Oncotarget 7, 18965\u201318977 (2016).","journal-title":"Oncotarget"},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4161\/cc.11.2.18813","volume":"11","author":"XS Deng","year":"2012","unstructured":"Deng, X. S. et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11, 367\u2013376 (2012).","journal-title":"Cell Cycle"},{"key":"256_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.59","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng, Y. et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 5, e1088 (2014).","journal-title":"Cell Death Dis."},{"key":"256_CR33","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","volume":"20","author":"L Li","year":"2014","unstructured":"Li, L. et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res. 20, 2714\u20132726 (2014).","journal-title":"Clin. Cancer Res."},{"key":"256_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1165\/rcmb.2012-0244OC","volume":"49","author":"CC Lin","year":"2013","unstructured":"Lin, C. C. et al. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am. J. Respir. Cell Mol. Biol. 49, 241\u2013250 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"256_CR35","doi-asserted-by":"publisher","first-page":"e95884","DOI":"10.1371\/journal.pone.0095884","volume":"9","author":"Z Zhao","year":"2014","unstructured":"Zhao, Z. et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One 9, e95884 (2014).","journal-title":"PLoS One"},{"key":"256_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-015-0183-0","volume":"34","author":"Q Pan","year":"2015","unstructured":"Pan, Q. et al. Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways. J. Exp. Clin. Cancer Res. 34, 77 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"256_CR37","doi-asserted-by":"crossref","first-page":"28235","DOI":"10.18632\/oncotarget.8595","volume":"7","author":"Q Liu","year":"2016","unstructured":"Liu, Q. et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2\/PGE2\/STAT3 axis. Oncotarget 7, 28235\u201328246 (2016).","journal-title":"Oncotarget"},{"key":"256_CR38","doi-asserted-by":"crossref","first-page":"21208","DOI":"10.18632\/oncotarget.4126","volume":"6","author":"W Yue","year":"2015","unstructured":"Yue, W. et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6, 21208\u201321224 (2015).","journal-title":"Oncotarget"},{"key":"256_CR39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.exphem.2016.08.005","volume":"44","author":"I Kawashima","year":"2016","unstructured":"Kawashima, I. & Kirito, K. Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56alpha subunit. Exp. Hematol. 44, 1156\u20131165 (2016). e1154.","journal-title":"Exp. Hematol."},{"key":"256_CR40","doi-asserted-by":"publisher","first-page":"18177","DOI":"10.1074\/jbc.M600064200","volume":"281","author":"C Walz","year":"2006","unstructured":"Walz, C. et al. Activated Jak2 with the V617F point mutation promotes G1\/S phase transition. J. Biol. Chem. 281, 18177\u201318183 (2006).","journal-title":"J. Biol. Chem."},{"key":"256_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canlet.2006.10.017","volume":"251","author":"DA Frank","year":"2007","unstructured":"Frank, D. A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199\u2013210 (2007).","journal-title":"Cancer Lett."},{"key":"256_CR42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/emboj\/18.5.1367","volume":"18","author":"I Matsumura","year":"1999","unstructured":"Matsumura, I. et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 18, 1367\u20131377 (1999).","journal-title":"EMBO J."},{"key":"256_CR43","doi-asserted-by":"publisher","first-page":"13916","DOI":"10.1073\/pnas.1508514112","volume":"112","author":"L Fabris","year":"2015","unstructured":"Fabris, L. et al. p27kip1 controls H-Ras\/MAPK activation and cell cycle entry via modulation of MT stability. Proc. Natl. Acad. Sci. USA 112, 13916\u201313921 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"256_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/21541248.2016.1171279","volume":"7","author":"G Baldassarre","year":"2016","unstructured":"Baldassarre, G. & Belletti, B. Meet me in the cytoplasm: A role forp27(Kip1) in the control of H-Ras. Small GTPases 7, 71\u201375 (2016).","journal-title":"Small GTPases"},{"key":"256_CR45","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.6177045","volume":"216","author":"P Martin","year":"1982","unstructured":"Martin, P. & Papayannopoulou, T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216, 1233\u20131235 (1982).","journal-title":"Science"},{"key":"256_CR46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/sj.leu.2401608","volume":"14","author":"K Uozumi","year":"2000","unstructured":"Uozumi, K. et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 14, 142\u2013152 (2000).","journal-title":"Leukemia"},{"key":"256_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607\u2013614 (2000). Pt 3.","journal-title":"Biochem. J."},{"key":"256_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbabio.2010.09.003","volume":"1807","author":"G Solaini","year":"2011","unstructured":"Solaini, G., Sgarbi, G. & Baracca, A. Oxidative phosphorylation in cancer cells. Biochim. Biophys. Acta 1807, 534\u2013542 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"256_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.tem.2010.06.005","volume":"21","author":"Z Cheng","year":"2010","unstructured":"Cheng, Z., Tseng, Y. & White, M. F. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21, 589\u2013598 (2010).","journal-title":"Trends Endocrinol. Metab."},{"key":"256_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3365","volume":"12","author":"DC Wallace","year":"2012","unstructured":"Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685\u2013698 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"256_CR51","first-page":"219","volume":"50","author":"EJ Freireich","year":"1966","unstructured":"Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H. & Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219\u2013244 (1966).","journal-title":"Cancer Chemother. Rep."},{"key":"256_CR52","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM199303043280904","volume":"328","author":"B Lowenberg","year":"1993","unstructured":"Lowenberg, B., van Putten, W. L., Touw, I. P., Delwel, R. & Santini, V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 328, 614\u2013619 (1993).","journal-title":"N. Engl. J. Med."},{"key":"256_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-8722-2-51","volume":"2","author":"Y Yan","year":"2009","unstructured":"Yan, Y. et al. Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias. J. Hematol. Oncol. 2, 51 (2009).","journal-title":"J. Hematol. Oncol."},{"key":"256_CR54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"256_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584\u2013596 (2010).","journal-title":"Cancer Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0256-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:52:20Z","timestamp":1671537140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-017-0256-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1038\/s41419-017-0256-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"2 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"311"}}